基本信息

教育背景

2001-09 至2007-07 北京工业大学生命科学与生物工程学院，博士研究生。

1988-09 至1991-03 北京工业大学化学与环境工程学系，硕士研究生。

1984-09 至1988-07 南京理工大学化学工程系，本科。

工作经历

2020-今 北京工业大学环境与生命学部，教授

2017-2020 北京工业大学生命科学与生物工程学院，教授

2005-2017北京工业大学生命科学与生物工程学院，副研究员

2002-2005 北京工业大学生命科学与生物工程学院，讲师

1991-2005 北京工业大学环境与能源工程学院，助教、讲师

研究方向

生物信息学

课程教学

主讲《生物医学统计》、《生物材料》、《生物信息学》、《学术报告》等课程

科研项目

(1) 北京市基金面上项目、2202002、用深度学习方法研究长链非编码RNA与蛋白质相互作用的分子机制、2020/01-2022/12、20万元、在研、主持。

(2) 国家自然科学基金面上项目、31971180、 基于全原子和粗粒化模型的蛋白质-RNA相互作用动力学及功能性构象变化的研究、2020/01-2023/12、69万元、在研、参加。

(3) 国家自然科学基金面上项目、21173014、抗HIV融合抑制剂的设计及其作用机理研究、2012/01-2015/12、61万元、结题、主持。

(4) 国家自然科学基金面上项目、31171267、基于RNA分子柔性分析的蛋白质-RNA分子对接方法研究、2012/01-2015/12、45万元、结题、参加。

(5) 国家重大基础研究发展计划（973计划）、2009CB930203、载药纳米颗粒的药效学、生物利用度及机理研究、2009/01-2013/08、672万元、已结题、参加。

(6) 科技部国际合作项目、2010DFA31710、纳米技术与理论计算相结合的环境监测方法合作研究、2010/06-2013/05、100万元、已结题、参加。

(7) 国家自然科学基金面上项目、30400087、蛋白质与蛋白质相互作用及对接方法的研究、2005/01-2007/12、22万元、已结题、参加。

(8) 国家自然科学基金面上项目、20042001、双区理论所揭示的致癌机理的实验证明和理论检验、2000/01-2002/12、8.8万元、已结题、参加。

(9) 国家自然科学基金面上项目、致癌机理双区理论的实验证明和理论检验、29742002、1997/05-1998/04、4万元、已结题、参加。

主要论文论著（*表示通讯作者）

[1] Wang J, Zhao Y, Gong W, Liu Y, Wang M, Huang X,Tan J*. EDLMFC: an ensemble deep learning framework with multi-scale features combination for ncRNA-protein interaction prediction. BMC Bioinformatics, 2021, 22(1):133.

[2] Men, J. R.;Tan, J. J*.; Sun, H. L. The Identification and Analysis of a miRNA Risk Score Model for Hepatocellular Carcinoma Prognosis.Prog. Biochem. Biophys.2020,47(4), 344-360, DOI: 10.16476/j.pibb.2019.0286.

[3] Tang, T.; Du, X. Y.; Zhang, X. Y.; Niu, W. L.; Li, C. H.;Tan, J. J.Computational identification and analysis of early diagnostic biomarkers for kidney cancer.J. Hum. Genet.2019,64(10), 1015-1022, DOI: 10.1038/s10038-019-0640-2.

[4] Cheng, S. P.; Zhang, L.;Tan, J. J*.; Gong, W. K.; Li, C. H.; Zhang, X. Y. DM-RPIs: Predicting ncRNA-protein interactions using stacked ensembling strategy.Comput. Biol. Chem.2019,83, DOI: 10.1016/j.compbiolchem.2019.107088.

[5] Liu, W.; An, X.; Wang, J.; Zhang, X.;Tan, J.; Zhou, Z.; Zeng, Y. A novel peptide shows excellent anti-HIV-1 potency as a gp41 fusion inhibitor.Bioorg Med Chem Lett2018,28(5), 910-914, DOI: 10.1016/j.bmcl.2018.01.061.

[6] Zhang, Z.; Lu, L.; Zhang, Y.; Hua Li, C.; Wang, C. X.; Zhang, X. Y.;Tan, J. J. A combinatorial scoring function for protein-RNA docking.Proteins2017,85(4), 741-752, DOI: 10.1002/prot.25253.

[7] Zhang, L.;Tan, J*.; Han, D.; Zhu, H. From machine learning to deep learning: progress in machine intelligence for rational drug discovery.Drug Discov. Today2017,22(11), 1680-1685, DOI: 10.1016/j.drudis.2017.08.010.

[8] Lv, D.; Wang, C.; Li, C.;Tan, J.; Zhang, X. An efficient perturbation method to predict the functionally key sites of glutamine binding protein.Comput. Biol. Chem.2017,67, 62-68, DOI: 10.1016/j.compbiolchem.2016.12.003.

[9]Tan, J*.; Yuan, H.; Li, C.; Zhang, X.; Wang, C. Insights into the Functions of M-T Hook Structure in HIV Fusion Inhibitor Using Molecular Modeling.Comput. Biol. Chem.2016,61, 202-9, DOI: 10.1016/j.compbiolchem.2016.01.006.

[10]Tan, J*.; Su, M.; Zeng, Y.; Wang, C. Design, synthesis and activity evaluation of novel peptide fusion inhibitors targeting HIV-1 gp41.Bioorg. Med. Chem.2016,24(2), 201-206, DOI:http://dx.doi.org/10.1016/j.bmc.2015.12.003.

[11] Lv, D. S.; Li, C. H.;Tan, J. J.; Zhang, X. Y.; Wang, C. X.; Su, J. G. Identification of functionally key residues in maltose transporter with an elastic network model-based thermodynamic method.Mol. Phys.2016,114(22), 3407-3417, DOI: 10.1080/00268976.2016.1234077.

[12] Han, D.; Su, M.;Tan, J. J*.; Li, C. H.; Zhang, X. Y.; Wang, C. X. Structure-activity relationship and binding mode studies for a series of diketo-acids as HIV integrase inhibitors by 3D-QSAR, molecular docking and molecular dynamics simulations.Rsc Adv2016,6(33), 27594-27606, DOI: 10.1039/c6ra00713a.

[13] Xie, X. L.; Li, C. H.; Yang, Y. X.; Jin, L.;Tan, J. J.; Zhang, X. Y.; Su, J. G.; Wang, C. X. Allosteric transitions of ATP-binding cassette transporter MsbA studied by the adaptive anisotropic network model.Proteins2015,83(9), 1643-53, DOI: 10.1002/prot.24850.

[14] Su, M.;Tan, J*.; Lin, C. Y. Development of HIV-1 integrase inhibitors: recent molecular modeling perspectives.Drug Discov. Today2015,20(11), 1337-48, DOI: 10.1016/j.drudis.2015.07.012.

[15]谭建军*; 张一平; 门婧睿 一种基于三维定量构效关系模型的一致性模型构建方法. CN104834831A, 2015-08-12, 2015.

[16] Zhang, X. Y.; Deng, D. J.;Tan, J. J.; He, Y.; Li, C. H.; Wang, C. X. Pharmacophore and Docking-based 3D-QSAR Studies on HIV-1 Integrase Inhibitors.Chem. Res. Chin. Univ.2014,30(2), 297-305, DOI: DOI 10.1007/s40242-014-3395-5.

[17] Zhang, H. G. C.; Li, C. H.; Yang, F.; Su, J. G.;Tan, J. J.; Zhang, X. Y.; Wang, C. X. Cation-pi Interactions at Non-redundant Protein-RNA Interfaces.Biochemistry-Moscow2014,79(7), 643-652, DOI: Doi 10.1134/S0006297914070062.

[18] Ma, X.;Tan, J*.; Su, M.; Li, C.; Zhang, X.; Wang, C. Molecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanism.PLoS One2014,9(11), e111923, DOI: 10.1371/journal.pone.0111923.

[19] Liu, W.;Tan, J. J*.; Mehryar, M. M.; Teng, Z. P.; Zeng, Y. Peptide HIV fusion inhibitors: modifications and conjugations.MedChemComm2014,5(10), 1472-1482, DOI: Doi 10.1039/C4md00214h.

[20] Li, S.; Liu, B.; Li, C. H.;Tan, J. J.; Zhang, X. Y.; Wang, C. X. E92A Is an Activity Recovery Mutation of HIV-1 Integrase Drug Resistance Mutation N155S.Prog. Biochem. Biophys.2014,41(5), 472-479, DOI: Doi 10.3724/Sp.J.1206.2013.00300.

[21] Li, C. H.; Yang, Y. X.; Su, J. G.; Liu, B.;Tan, J. J.; Zhang, X. Y.; Wang, C. X. Allosteric Transitions of the Maltose Transporter Studied by an Elastic Network Model.Biopolymers2014,101(7), 758-768, DOI: Doi 10.1002/Bip.22455.

[22] Xu, X. J.; Su, J. G.; Liu, B.; Li, C. H.;Tan, J. J.; Zhang, X. Y.; Chen, W. Z.; Wang, C. X. Reverse Virtual Screening on Persistent Organic Pollutants 4,4 '-DDE and CB-153.Acta Phys-Chim Sin2013,29(10), 2276-2285, DOI: 10.3866/pku.whxb201307161.

[23]Tan, J. J.; Wang, Y.; Wang, C. X. Quantitative Structure-Activity RElationship of Anti-HIV Fusion Inhibitors by Topomer CoMFA.Journal of Beijing University of Technology2013,39(2), 309-313.

[24] Tan, J. J.; Wang, C. X. The Development of Novel Inhibitors for the Treatment of HIV Infection.Curr. Pharm. Des.2013,19(10), 1765-1766.

[25]Tan, J. J.; Ma, X. T.; Liu, C.; Zhang, X. Y.; Wang, C. X. The Current Status and Challenges in the Development of Fusion Inhibitors as Therapeutics for HIV-1 Infection.Curr. Pharm. Des.2013,19(10), 1810-1817.

[26] Sun, X. H.; Guan, J. Q.;Tan, J. J*.; Liu, C.; Wang, C. X. InExploring quinoline ring derivatives as potent integrase inhibitors using ligand-based modeling studies, World Congress on Medical Physics and Biomedical Engineering, May 26, 2012 - May 31, 2012, Beijing, China, Springer Verlag: Beijing, China, 2013; pp 1276-1279.

[27] Ma, X. T.; Sun, X. H.;Tan, J. J*.; Wang, C. X. InDevelopment of peptide fusion inhibitors targeting HIV-1 gp41, World Congress on Medical Physics and Biomedical Engineering, May 26, 2012 - May 31, 2012, Beijing, China, Springer Verlag: Beijing, China, 2013; pp 2221-2223.

[28] Liu, X.;Tan, J. J*.; Chen, W. Z.; Liu, B.; Li, S.; Wang, C. X. Support Vector Machine Applied to Predicting the Activity of HIV－1 IN Inhibitors.Journal of Beijing University of Technology2013,39(4), 634-640.

[29]谭建军*; 苑红领; 曾毅; 李春华; 刘斌; 张小轶; 王存新 抑制HIV病毒与宿主细胞融合的非对映体多肽及其用途. 2014-4-16, 2013.

[30]Tan, J. J*.; Liu, C.; Sun, X. H.; Cong, X. J.; Hu, L. M.; Wang, C. X.; Liang, X. J. Perspectives on Developing Small Molecule Inhibitors Targeting HIV-1 Integrase.Mini-Rev. Med. Chem.2012,12(9), 875-889.

[31] Sun, X. H.; Guan, J. Q.;Tan, J. J*.; Liu, C.; Wang, C. X. 3D-QSAR studies of quinoline ring derivatives as HIV-1 integrase inhibitors.SAR QSAR Environ. Res.2012,23(7-8), 683-703, DOI: 10.1080/1062936x.2012.717541.

[32]Tan, J. J.; Zhang, B.; Cong, X. J.; Yang, L. F.; Liu, B.; Kong, R.; Kui, Z. Y.; Wang, C. X.; Hu, L. M. Computer-Aided Design, Synthesis, and Biological Activity Evaluation of Potent Fusion Inhibitors Targeting HIV-1 gp41.Med. Chem.2011,7(4), 309-316.

[33]Tan, J. J.; Sun, X. H.; Liu, B.; Wang, C. X., Computer-aided Design, Synthesis, and Biological Activity Evaluation of Potent Fusion Inhibitors Targeting HIV-1 gp41. In17^thInetrnational Biophysics Congress, Beijing 2011; pp 404-405.

[34] Li, P.; Liu, M.;Tan, J. J.; Zhang, X. Y.; Chen, W. Z.; Wang, C. X. Insight into the Inhibitory Mechanism and Binding Mode Between D77 and HIV-1 Integrase by Molecular Modeling MethodsJournal of Biomolcular Structure and Dynamics2011,29(2), 251-423.

[35]Tan, J. J.; Cong, X. J.; Hu, L. M.; Wang, C. X.; Jia, L.; Liang, X. J. Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection.Drug Discov. Today2010,15(5-6), 186-197, DOI: 10.1016/j.drudis.2010.01.004.

[36] Luo, Z. G.;Tan, J. J.; Zeng, Y.; Wang, C. X.; Hu, L. M. Development of Integrase Inhibitors of Quinolone Acid Derivatives for Treatment of AIDS: An Overview.Mini-Rev. Med. Chem.2010,10(11), 1046-1057.

[37] Jiao, Z. G.; He, H. Q.; Zeng, C. C.;Tan, J. J.; Hu, L. M.; Wang, C. X. Design, Synthesis and Anti-HIV Integrase Evaluation of N-(5-Chloro-8-Hydroxy-2-Styrylquinolin-7-yl)Benzenesulfonamide Derivatives.Molecules2010,15(3), 1903-1917, DOI: 10.3390/molecules15031903.

[38] Cong, X. J.;Tan, J. J.; Liu, M.; Chen, W. Z.; Wang, C. X. Computational Study of Binding Mode for N-substituted Pyrrole Derivatives to HIV-1 gp41.Prog. Biochem. Biophys.2010,37(8), 904-915, DOI: 10.3724/sp.j.1206.2010.00110.

[39] Liu, M.; Cong, X. J.; Li, P.;Tan, J. J.; Chen, W. Z.; Wang, C. X. Study on the Inhibitory Mechanism and Binding Mode of the Hydroxycoumarin Compound NSC158393 to HIV-1 Integrase by Molecular Modeling.Biopolymers2009,91(9), 700-709, DOI: 10.1002/bip.21211.

[40] Liu, M.; Su, J. G.; Kong, R.; Sun, T. G.;Tan, J. J.; Chen, W. Z.; Wang, C. X. Molecular dynamics simulations of the bacterial periplasmic heme binding proteins ShuT and PhuT.Biophys. Chem.2008,138(1-2), 42-49, DOI: 10.1016/j.bpc.2008.09.001.

[41]Tan, J. J.; Chen, W. Z.; Wang, C. X. Investigating interactions between HIV-1 gp41 and inhibitors by molecular dynamics simulation and MM-PBSA/GBSA calculations.J. Mol. Struct. Theochem2006,766(2-3), 77-82, DOI: 10.1016/j.theochem.2006.02.022.

[42] Kong, R.;Tan, J. J.; Ma, X. H.; Chen, W. Z.; Wang, C. X. Prediction of the binding mode between BMS-378806 and HIV-1 gp120 by docking and molecular dynamics simulation.Bba-Proteins Proteom2006,1764(4), 766-772, DOI: 10.1016/j.bbapap.2005.12.017.

[43]Tan, J. J.; Kong, R.; Chen, W. Z.; Wang, C. X. Studies on binding free energies and the binding mode by docking and MM-PBSA in gp41-ligand complex.Mol. Simul.2005,31(14-15), 1051-1056, DOI: 10.1080/08927020500447132.

[44]Tan, J. J.; Kong, R.; Wang, C. X.; Chen, W. Z. Molecular dynamics simulation on the complexes of N-terminal region of HIV-1 gp41 and its C-peptide inhibitors.J. Mol. Struct. Theochem2004,682(1-3), 9-15, DOI: 10.1016/j.theochem.2004.05.016.

[45] Ma, X. H.; Zhang, X. Y.;Tan, J. J.; Chen, W. Z.; Wang, C. X. Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis and docking studies.Acta Pharmacol. Sin.2004,25(7), 950-958.

硕士研究生招生学科和研究方向

0831生物医学工程：03大数据与生物信息学

0854电子信息（专业学位）：03大数据与生物信息学